Intravitreal injections are the most commonly performed ophthalmologic procedure—more so even than cataract surgery—with over three million injections performed in 2016. With an aging population and an expected coinciding rise in retinal disease, studies suggest these numbers will only grow. One particular class, anti–vascular endothelial growth factor (VEGF) medications, can treat patients with various retinal conditions.
In an effort to prevent diabetic retinopathy (DR) from progressing to the point of referral, current and recent clinical trials have been exploring a new, earlier treatment strategy relying on anti-VEGF injections. This article provides an overview of ocular conditions associated with diabetes, discusses the success anti-VEGF treatment is achieving and offers a protocol for optometrists who work closely with these patients.
Millions of Americans suffer from a traumatic brain injury (TBI) each year, with nearly 75 percent of all those with TBI suffering from some form of visual dysfunction. Patients may come into the primary care optometrist’s office complaining about double vision, blurred vision, closing one eye, dizziness, headaches, sensitivity to lights, bumping into things and/or poor coordination.
You’ve taken the kids for their checkups and scheduled your parents’ doctor visits. You even went along to make sure they understand what was happening.
Nikki Iravani, OD, is always on the lookout for a great marketing tip.
Nine women ODs were honored during the fourth annual Theia Awards of Excellence from Women In Optometry magazine.